Loading company…
Ruizheng Gene develops gene and RNA editing technologies and therapies.
Founded in 2021 and based in Suzhou, China, Ruizheng Gene develops gene and RNA editing platforms and therapeutic candidates for congenital and acquired diseases. In August 2025, it raised CNY 75 million in Series A funding from Xizang Nuodikang Pharmaceutical and China Medical System Holdings Limited.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in